Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.43 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488813 | 0.90 | RAB9A (0.55) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL15779490 | 0.84 | NPC1 (0.51) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL5844385 | 0.83 | SLC2A1 (0.52) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL488660 | 0.82 | RAB9A (0.57) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL488757 | 0.82 | LTA4H (0.61) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL9126930 | 0.80 | NPC1 (0.55) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL9747086 | 0.80 | LTA4H (0.58) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL488298 | 0.80 | LTA4H (0.58) | NPC1RAB9AMAPTLTA4HMAPK14 | |
| SCHEMBL645561 | 0.79 | RAB9A (0.66) | NPC1RAB9AMAPTSMN1; SMN2HTT | |
| SCHEMBL488397 | 0.78 | LTA4H (0.53) | NPC1RAB9AMAPTLTA4HMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| WO-2014146486-A1 | THREE-LEVEL CYCLIC AMINE ALK KINASE INHIBITOR FOR TREATING CANCER | 浙江导明医药科技有限公司 (CN) | 2014-09-25 | — | — | WO | disclosed |
| EP-1603570-B9 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-1603570-B1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2476667-A2 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5409943-A | [(alkoxy)pyridinyl]amine compounds which are useful in the treatment of gastrointestinal disorders | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1995-04-25 | — | — | US | disclosed |
| EP-0625143-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1994-11-23 | — | — | EP | disclosed |
| CN-1089947-A | New heterogeneous ring compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-07-27 | — | — | CN | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
| WO-1993015055-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1993-08-05 | — | — | WO | disclosed |
| EP-0204285-B1 | IMIDAZOHETEROCYCLIC COMPOUNDS PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| US-4725601-A | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0204285-A1 | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | NPC1 3141/4885RAB9A 2869/4885MAPT 120/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | NPC1 3437/4885RAB9A 2752/4885MAPT 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.